We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
CONMED's product platforms offer growth potential through rising adoption and clinical differentiation.
Buffalo Filter could benefit as 23 states enact surgical smoke laws, covering nearly 60% of the population.
2026 EPS estimates rose 4 cents to $4.58 per share, despite tariff pressures and weak US orthopedic sales.
CONMED Corporation (CNMD - Free Report) is well positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Improving supply-chain bottlenecks should drive top- and bottom-line growth.
CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.
Shares of this Zacks Rank #3 (Hold) company have gained 25.1% in the year-to-date period, outperforming the industry’s 21.9% growth and the S&P 500 Index’s 8.8% rise.
Image Source: Zacks Investment Research
CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.53 billion. The company projects 4.7% earnings growth over the next five years.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.58%.
Factors Favoring CNMD Stock
AirSeal's da Vinci 5 Compatibility Supports Growth Potential: AirSeal remains an important growth engine for CONMED, supported by its clinical differentiation in complex robotic procedures and expanding compatibility with surgical platforms. The company reported stronger AirSeal growth in the third quarter, driven by stable disposable sales and robust capital equipment demand, particularly internationally.
CONMED's expanded U.S. indication for use with Intuitive Surgical's 8-millimeter da Vinci 5 cannulas also provides access to the growing installed base of robotic surgical systems. Clinical evidence showing improvements in procedure time, visualization and postoperative outcomes strengthens its value proposition. With U.S. laparoscopic penetration estimated at just 6-7%, substantial room remains for broader adoption.
Legislative Momentum Favorable for Buffalo Filter: CONMED's direct Buffalo Filter business is positioned to benefit from increasing regulatory attention to surgical smoke evacuation. During the third quarter, Michigan and Pennsylvania enacted legislation requiring facilities to implement smoke evacuation policies or use evacuation devices, bringing the total number of states with smoke-free operating room laws to 23, covering approximately 60% of the U.S. population.
More than 10 additional states are considering similar legislation. Given that an estimated 90% of surgical procedures generate smoke, the regulatory push addresses a substantial clinical need. CONMED's evidence demonstrating the filtration of virtually all toxic surgical smoke could support adoption and durable growth in its direct portfolio.
BioBrace's Strong Clinical Evidence Boosts Adoption: BioBrace is emerging as an important growth platform in CONMED's Orthopedic Surgery business, supported by its combination of mechanical reinforcement and bio-inductive properties. The product has demonstrated a 94% healing rate when used to augment rotator cuff repairs in high-risk patients. Its adoption opportunity is reinforced by American Academy of Orthopedic Surgeons guidelines that strongly recommend bio-inductive implants for these procedures, addressing a U.S. market of approximately 1 million annual rotator cuff repairs.
International expansion provides additional growth avenues, with regulatory clearance secured in Brazil during the third quarter. Robust uptake in authorized overseas markets suggests that the product's clinical advantages are gaining traction among surgeons.
Challenges for CNMD Stock
U.S. Orthopedic Weakness Raises Concerns: CONMED's U.S. Orthopedic Surgery business remains a key execution challenge as the company restructures its commercial organization. Although global Orthopedic Surgery sales grew 7.2% organically at constant currency in the third quarter, it reflected strong international growth of 12.7% that more than offset a 1.7% domestic decline.
Management attributed the U.S. weakness to organizational changes and the ongoing onboarding and operationalization of distributors. While year-over-year growth trends improved on both two- and three-year comparisons, management indicated that U.S. growth may not return to normalized levels until late 2026 or the first half of 2027. The extended recovery timeline creates uncertainty around near-term orthopedic performance.
OEM Buffalo Filter Weakness Adds Volatility: The decline in sales to OEM smoke evacuation customers remains a headwind for CONMED's General Surgery business. Although direct Buffalo Filter sales increased within management's targeted high-single-digit to low-double-digit range, softer OEM demand limited the overall contribution.
Management acknowledged that OEM ordering patterns are more variable because they depend on partners' individual business and supply-chain decisions. This limits CONMED's visibility into the timing and consistency of that revenue stream. The company is strategically prioritizing direct sales because of its stronger margin profile and closer customer relationships, but the transition may not immediately eliminate the volatility associated with its existing OEM business.
Distributor Order Timing Makes International Growth Less Predictable: CONMED's strong international performance in the third quarter may be difficult to replicate in the following quarter. International growth benefited partly from the timing of distributor orders, which management does not expect to recur to the same extent in the fourth quarter. This is significant because the international business is largely distribution-oriented, making reported quarterly performance susceptible to ordering fluctuations.
Although management maintained its underlying expectations for international performance, it acknowledged that the timing benefit would not be incorporated into the fourth-quarter outlook. The company consequently reduced the high end of its full-year organic constant-currency sales growth guidance from 6% to 5.5%, reflecting a more measured sequential improvement.
CONMED is witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 4 cents to $4.58 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues and EPS is pegged at $366.7 million and $1.27, respectively, suggesting a decline of 1.7% and 11.2% from the year-ago reported numbers.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
Key Takeaways
CONMED Corporation (CNMD - Free Report) is well positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Improving supply-chain bottlenecks should drive top- and bottom-line growth.
CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern.
Shares of this Zacks Rank #3 (Hold) company have gained 25.1% in the year-to-date period, outperforming the industry’s 21.9% growth and the S&P 500 Index’s 8.8% rise.
Image Source: Zacks Investment Research
CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.53 billion. The company projects 4.7% earnings growth over the next five years.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.58%.
Factors Favoring CNMD Stock
AirSeal's da Vinci 5 Compatibility Supports Growth Potential: AirSeal remains an important growth engine for CONMED, supported by its clinical differentiation in complex robotic procedures and expanding compatibility with surgical platforms. The company reported stronger AirSeal growth in the third quarter, driven by stable disposable sales and robust capital equipment demand, particularly internationally.
CONMED's expanded U.S. indication for use with Intuitive Surgical's 8-millimeter da Vinci 5 cannulas also provides access to the growing installed base of robotic surgical systems. Clinical evidence showing improvements in procedure time, visualization and postoperative outcomes strengthens its value proposition. With U.S. laparoscopic penetration estimated at just 6-7%, substantial room remains for broader adoption.
Legislative Momentum Favorable for Buffalo Filter: CONMED's direct Buffalo Filter business is positioned to benefit from increasing regulatory attention to surgical smoke evacuation. During the third quarter, Michigan and Pennsylvania enacted legislation requiring facilities to implement smoke evacuation policies or use evacuation devices, bringing the total number of states with smoke-free operating room laws to 23, covering approximately 60% of the U.S. population.
More than 10 additional states are considering similar legislation. Given that an estimated 90% of surgical procedures generate smoke, the regulatory push addresses a substantial clinical need. CONMED's evidence demonstrating the filtration of virtually all toxic surgical smoke could support adoption and durable growth in its direct portfolio.
BioBrace's Strong Clinical Evidence Boosts Adoption: BioBrace is emerging as an important growth platform in CONMED's Orthopedic Surgery business, supported by its combination of mechanical reinforcement and bio-inductive properties. The product has demonstrated a 94% healing rate when used to augment rotator cuff repairs in high-risk patients. Its adoption opportunity is reinforced by American Academy of Orthopedic Surgeons guidelines that strongly recommend bio-inductive implants for these procedures, addressing a U.S. market of approximately 1 million annual rotator cuff repairs.
International expansion provides additional growth avenues, with regulatory clearance secured in Brazil during the third quarter. Robust uptake in authorized overseas markets suggests that the product's clinical advantages are gaining traction among surgeons.
Challenges for CNMD Stock
U.S. Orthopedic Weakness Raises Concerns: CONMED's U.S. Orthopedic Surgery business remains a key execution challenge as the company restructures its commercial organization. Although global Orthopedic Surgery sales grew 7.2% organically at constant currency in the third quarter, it reflected strong international growth of 12.7% that more than offset a 1.7% domestic decline.
Management attributed the U.S. weakness to organizational changes and the ongoing onboarding and operationalization of distributors. While year-over-year growth trends improved on both two- and three-year comparisons, management indicated that U.S. growth may not return to normalized levels until late 2026 or the first half of 2027. The extended recovery timeline creates uncertainty around near-term orthopedic performance.
OEM Buffalo Filter Weakness Adds Volatility: The decline in sales to OEM smoke evacuation customers remains a headwind for CONMED's General Surgery business. Although direct Buffalo Filter sales increased within management's targeted high-single-digit to low-double-digit range, softer OEM demand limited the overall contribution.
Management acknowledged that OEM ordering patterns are more variable because they depend on partners' individual business and supply-chain decisions. This limits CONMED's visibility into the timing and consistency of that revenue stream. The company is strategically prioritizing direct sales because of its stronger margin profile and closer customer relationships, but the transition may not immediately eliminate the volatility associated with its existing OEM business.
Distributor Order Timing Makes International Growth Less Predictable: CONMED's strong international performance in the third quarter may be difficult to replicate in the following quarter. International growth benefited partly from the timing of distributor orders, which management does not expect to recur to the same extent in the fourth quarter. This is significant because the international business is largely distribution-oriented, making reported quarterly performance susceptible to ordering fluctuations.
Although management maintained its underlying expectations for international performance, it acknowledged that the timing benefit would not be incorporated into the fourth-quarter outlook. The company consequently reduced the high end of its full-year organic constant-currency sales growth guidance from 6% to 5.5%, reflecting a more measured sequential improvement.
CONMED Corporation Price and Consensus
CONMED Corporation price-consensus-chart | CONMED Corporation Quote
Estimate Trend
CONMED is witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has improved 4 cents to $4.58 per share.
The Zacks Consensus Estimate for fourth-quarter 2026 revenues and EPS is pegged at $366.7 million and $1.27, respectively, suggesting a decline of 1.7% and 11.2% from the year-ago reported numbers.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.